Primary Care Strategies to Reduce High Blood Pressure: A Cluster Randomized Trial in Rural Bangladesh, Pakistan and Sri Lanka (COBRA-BPS)

October 29, 2019 updated by: Professor Tazeen Jafar, Duke-NUS Graduate Medical School

Control of Blood Pressure and Risk Attenuation-Bangladesh, Pakistan and Sri Lanka (COBRA-BPS)

Background: High blood pressure (BP) is the leading attributable risk for cardiovascular disease (CVD). In rural South Asia, hypertension remains to be a significant public health issue with sub-optimal rates of case finding and management. The goal of the full-scale study is to evaluate the effectiveness and cost-effectiveness of multicomponent primary care strategies on lowering blood pressure among adults with hypertension in rural communities in Bangladesh, Pakistan, and Sri Lanka.

Methods/Design: The mixed-methods, stratified cluster randomized controlled trial

Intervention: The multi-component interventions (MCI) is comprised of all the following five components: 1) home health education (HHE) by government community health workers (CHWs), plus 2) blood pressure (BP) monitoring and stepped-up referral to a trained general practitioner (GP) using a checklist, plus 3) training public and private providers in management of hypertension and using a checklist, plus 4) designating hypertension triage counter and hypertension care coordinators in government clinics, plus 5) a financing model to compensate for additional health services and provide subsides to low income individuals with poorly controlled hypertension.

Usual care: Will comprise existing services in the community without any additional training.

Participants: The trial will be conducted on 2550 individuals aged 40 years or older with hypertension (systolic BP ≥ 140 mm Hg or diastolic BP≥ 90 mm Hg, or on antihypertensive therapy) in 30 rural communities of Bangladesh, Pakistan and Sri Lanka. Out of the 2550 individuals, 420 with poorly controlled BP (Systolic BP≥160 mmHg or Diastolic BP≥100 mmHg) will be selected, 14 from each community, to investigate the effect of MCI on results from ambulatory BP monitoring.

Qualitative component: Stakeholders including policymakers, district managers, and community health workers, GPs, hypertensive individuals and family members in the identified clusters will be surveyed.

Outcome: The primary outcome will be change in systolic BP from baseline to follow-up at 24 months post randomization. The cost effectiveness outcome is the incremental cost of MCI per unit reduction in BP over the two year time period and in terms of incremental cost per CVD DALYs averted.

Study Overview

Status

Unknown

Conditions

Study Type

Interventional

Enrollment (Anticipated)

2550

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Main study:

Inclusion Criteria:

  1. Age≥ 40 years
  2. Residing in the selected clusters
  3. Hypertension defined either as:

    1. Persistently elevated BP (systolic BP ≥140 mm Hg or diastolic BP ≥90 mm Hg) from each set of last 2 of 3 readings from 2 separate days
    2. maintained on anti-hypertensive medications
  4. Informed consent

Exclusion Criteria:

  1. Permanently bed-ridden individuals too ill to commute to the clinic
  2. Pregnancy, or individuals with advanced medical disease (on dialysis, liver failure, other systemic diseases)
  3. Individuals that are mentally compromised and unable to give informed consent

Sub-study:

1) fulfill all criteria of main study and, 2) Persistently elevated systolic BP >160 mm Hg or diastolic BP >100 mm Hg from each set of 2 readings from 2 separate days

-

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: usual care
Usual care comprises existing services for hypertension control in the community without any additional training
Experimental: multi-component interventions
: The multi-component interventions (MCI) is comprised of all the following five components: 1) home health education (HHE) by government community health workers (CHWs), plus 2) blood pressure (BP) monitoring and stepped-up referral to a trained general practitioner (GP) using a checklist, plus 3) training public and private providers in management of hypertension and using a checklist, plus 4) designating hypertension triage counter and hypertension care coordinators in government clinics, plus 5) a financing model to compensate for additional health services and provide subsides to low income individuals with poorly controlled hypertension.
The multi-component interventions (MCI) is comprised of all the following five components: 1) home health education (HHE) by government community health workers (CHWs), plus 2) blood pressure (BP) monitoring and stepped-up referral to a trained general practitioner (GP) using a checklist, plus 3) training public and private providers in management of hypertension and using a checklist, plus 4) designating hypertension triage counter and hypertension care coordinators in government clinics, plus 5) a financing model to compensate for additional health services and provide subsides to low income individuals with poorly controlled hypertension.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Blood pressure reading:change in systolic blood pressure (SBP) from baseline to follow-up at 24 months post randomization.
Time Frame: Blood pressure (BP) will measured at baseline and then at 6-month intervals until 24 months after randomization
Blood pressure (BP) will measured at baseline and then at 6-month intervals until 24 months after randomization

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Blood pressure reading:Blood Pressure(BP) controlled to target (Systolic BP <140 mm Hg and Diastolic BP <90 mm
Time Frame: at 6-month intervals over 24 months
at 6-month intervals over 24 months
Questionnaire:Composite outcome of death (all cause), or hospital admission due to coronary heart disease (CHD), heart failure, or stroke
Time Frame: 24 months
24 months
Questionnaire and EQ-5D-5L:Incremental cost per quality-adjusted life-year (QALY) gained from baseline to end of follow-up
Time Frame: 24 months
24 months
Morisky Medication Adherence Scale(MMAS):Change in antihypertensive medication adherence (Morisky score)
Time Frame: 24 months
24 months
Height and weight measurements:change in body mass index ( BMI)
Time Frame: 24 months
24 months
questionnaire:change dietary salt intake (urinary excretion)
Time Frame: 24 months
24 months
Questionnaire:change in prevalence of current smokers
Time Frame: 24 months
24 months
Questionnaire:incident diabetes
Time Frame: 24 months
24 months
Lipid panel: change in serum lipid levels
Time Frame: 24 months
24 months
questionnaire: change in INTERHEART cardiovascular disease (CVD) risk score
Time Frame: 24 months
24 months
Questionnaire:incidence of adverse outcomes (medication side effects, sick days absenteeism, low QALY between randomized groups).
Time Frame: 24 months
24 months
Questionnaire and serum creatinine:Change in estimated glomerular filtration rate (eGFR)
Time Frame: 24 months
24 months
Urine albumin:Change in urine albumin
Time Frame: 24 months
24 months
24 hours mean diastolic BP
Time Frame: 24 months
Secondary outcome for the sub-study of 420 patients with poorly controlled BP at baseline
24 months
Daytime SBP/DBP
Time Frame: 24 months
secondary outcome for the sub-study of 420 patients with poorly controlled BP at baseline
24 months
Night time SBP/DBP
Time Frame: 24 months
Secondary outcome for the sub-study of 420 patients with poorly controlled BP at baseline
24 months
Dipping Pattern
Time Frame: 24 months
Secondary outcome for the sub-study of 420 patients with poorly controlled BP at baseline
24 months
24 hour BP variability
Time Frame: 24 months
Secondary outcome for the sub-study of 420 patients with poorly controlled BP at baseline
24 months
Questionnaire and EQ-5D-5L:Incremental cost per mm Hg BP reduction from baseline to end of follow-up at two years post randomization and incremental cost per projected cardiovascular disease ( CVD) disability adjusted life year (DALY) averted
Time Frame: information on healthcare cost will be collected at baseline and 24 months
information on healthcare cost will be collected at baseline and 24 months
incremental cost per mm Hg BP reduction from baseline to end of follow-up at 2 years post-randomization and incremental cost per projected CVD disability-adjusted life year (DALY) averted
Time Frame: 24 months
24 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Tazeen H Jafar, MD,MPH, Duke-NUS Medical School (Singapore)

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 1, 2016

Primary Completion (Actual)

March 1, 2019

Study Completion (Anticipated)

March 1, 2020

Study Registration Dates

First Submitted

January 14, 2016

First Submitted That Met QC Criteria

January 15, 2016

First Posted (Estimate)

January 18, 2016

Study Record Updates

Last Update Posted (Actual)

October 31, 2019

Last Update Submitted That Met QC Criteria

October 29, 2019

Last Verified

October 1, 2019

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hypertension

Clinical Trials on multi-component interventions

3
Subscribe